Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Washington University School of Medicine
Ruijin Hospital
French Innovative Leukemia Organisation
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
University of Maryland, Baltimore
Tata Memorial Centre
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Ruijin Hospital
Hospital Universitario Dr. Jose E. Gonzalez
Technische Universität Dresden
Beijing 302 Hospital
Ludwig-Maximilians - University of Munich
St. Anna Kinderkrebsforschung
M.D. Anderson Cancer Center
Goethe University
Beijing 302 Hospital
University of British Columbia
Therapeutic Advances in Childhood Leukemia Consortium
Fred Hutchinson Cancer Center
Amgen Research (Munich) GmbH
Nanfang Hospital, Southern Medical University
M.D. Anderson Cancer Center
Amgen Research (Munich) GmbH
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
M.D. Anderson Cancer Center
Northern Italy Leukemia Group